151 related articles for article (PubMed ID: 36807750)
1.
Flores Legarreta A; Salvo G; Gonzales NR; Chisholm G; Hillman RT; Frumovitz M
J Gynecol Oncol; 2023 Jul; 34(4):e50. PubMed ID: 36807750
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
[TBL] [Abstract][Full Text] [Related]
3. Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
Hillman RT; Cardnell R; Fujimoto J; Lee WC; Zhang J; Byers LA; Ramalingam P; Leitao M; Swisher E; Futreal PA; Frumovitz M
PLoS One; 2020; 15(6):e0234505. PubMed ID: 32544169
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
5. Imaging and staging of neuroendocrine cervical cancer.
Elsherif S; Odisio EGLC; Faria S; Javadi S; Yedururi S; Frumovitz M; Ramalingam P; Bhosale P
Abdom Radiol (NY); 2018 Dec; 43(12):3468-3478. PubMed ID: 29974177
[TBL] [Abstract][Full Text] [Related]
6. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
[TBL] [Abstract][Full Text] [Related]
7. Patterns of recurrence and survival in neuroendocrine cervical cancer.
Stecklein SR; Jhingran A; Burzawa J; Ramalingam P; Klopp AH; Eifel PJ; Frumovitz M
Gynecol Oncol; 2016 Dec; 143(3):552-557. PubMed ID: 27645621
[TBL] [Abstract][Full Text] [Related]
8. Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix.
Goto S; Terao Y; Kamigaki T; Takimoto R; Naitoh K; Makita K; Yasumoto K; Okada S; Takizawa K; Yokomichi N; Suzuki N; Takeda S
Anticancer Res; 2020 Aug; 40(8):4741-4748. PubMed ID: 32727800
[TBL] [Abstract][Full Text] [Related]
9. PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study.
Frumovitz M; Morani AC; Aziz A; Jhingran A; Ramalingam P; Gonzales NR; Salvo G; Sun J; Bhosale P
Int J Gynecol Cancer; 2023 Nov; 33(11):1690-1694. PubMed ID: 37875320
[TBL] [Abstract][Full Text] [Related]
10. Natural history and outcome of neuroendocrine carcinoma of the cervix.
Margolis B; Tergas AI; Chen L; Hou JY; Burke WM; Hu JC; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2016 May; 141(2):247-254. PubMed ID: 26873865
[TBL] [Abstract][Full Text] [Related]
11. Exploring a Better Adjuvant Treatment for Surgically Treated High-Grade Neuroendocrine Carcinoma of the Cervix.
Wang R; Xiao Y; Ma L; Wu Z; Xia H
Gynecol Obstet Invest; 2022; 87(6):398-405. PubMed ID: 36273460
[TBL] [Abstract][Full Text] [Related]
12. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
13. Distant organ metastasis patterns and prognosis of neuroendocrine cervical carcinoma: a population-based retrospective study.
Li Q; Yu J; Yi H; Lan Q
Front Endocrinol (Lausanne); 2022; 13():924414. PubMed ID: 36051393
[TBL] [Abstract][Full Text] [Related]
14. Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
Xing D; Zheng G; Schoolmeester JK; Li Z; Pallavajjala A; Haley L; Conner MG; Vang R; Hung CF; Wu TC; Ronnett BM
Am J Surg Pathol; 2018 Jun; 42(6):750-760. PubMed ID: 29505425
[TBL] [Abstract][Full Text] [Related]
15. Association of P16-RBSP3 inactivation with phosphorylated RB1 overexpression in basal-parabasal layers of normal cervix unchanged during CACX development.
Chakraborty C; Roychowdhury A; Samadder S; Roy A; Mandal RK; Basu P; Roychoudhury S; Panda CK
Biochem J; 2016 Oct; 473(19):3221-36. PubMed ID: 27458253
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and molecular abnormalities of primary grade 2 neuroendocrine tumors of the cervix.
Zhu R; Wu H; Chen B; Pang J; Huo Z
Diagn Pathol; 2019 Jun; 14(1):64. PubMed ID: 31228945
[TBL] [Abstract][Full Text] [Related]
17. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer.
Frumovitz M; Burzawa JK; Byers LA; Lyons YA; Ramalingam P; Coleman RL; Brown J
Gynecol Oncol; 2016 Jun; 141(3):588-591. PubMed ID: 27079212
[TBL] [Abstract][Full Text] [Related]
18. Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases.
Ordulu Z; Mino-Kenudson M; Young RH; Van de Vijver K; Zannoni GF; Félix A; Burandt E; Wong A; Nardi V; Oliva E
Am J Surg Pathol; 2022 Dec; 46(12):1670-1681. PubMed ID: 36069807
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
[TBL] [Abstract][Full Text] [Related]
20. The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
Pei X; Xiang L; Chen W; Jiang W; Yin L; Shen X; Zhou X; Yang H
Gynecol Oncol; 2021 Jun; 161(3):779-786. PubMed ID: 33888337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
